Grimes & Company Inc. Has $2.40 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Grimes & Company Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,468 shares of the company’s stock after selling 34 shares during the quarter. Grimes & Company Inc.’s holdings in IDEXX Laboratories were worth $2,396,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. MorganRosel Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth $26,000. Opal Wealth Advisors LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after buying an additional 30 shares during the period. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories during the second quarter worth about $36,000. Finally, WPG Advisers LLC acquired a new position in IDEXX Laboratories in the first quarter valued at about $37,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 in the last quarter. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 0.5%

Shares of NASDAQ:IDXX opened at $627.78 on Tuesday. The stock has a market capitalization of $50.22 billion, a PE ratio of 52.27, a price-to-earnings-growth ratio of 4.09 and a beta of 1.58. The company’s 50-day moving average price is $635.75 and its two-hundred day moving average price is $537.82. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business earned $2.44 earnings per share. IDEXX Laboratories’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IDXX. Morgan Stanley raised their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research report on Friday, August 15th. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Saturday, September 27th. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a report on Monday, August 4th. Finally, Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.